The Impact of Glucagon-Like Peptide-1 Agonists on Hip and Knee Arthroplasty and Perioperative Considerations

被引:5
|
作者
Jacofsky, David J. [1 ]
Springer, Bryan D. [2 ,3 ]
Mont, Michael A. [4 ]
Ushakumari, Deepu S. [5 ]
Sladen, Robert N. [6 ]
机构
[1] CORE Inst, Phoenix, AZ 85023 USA
[2] OrthoCarolina Hip & Knee Ctr, Charlotte, NC USA
[3] Atrium Musculoskeletal Inst, Charlotte, NC USA
[4] Rubin Inst Adv Orthoped, Baltimore, MD USA
[5] Scope Anesthesia North Carolina, Charlotte, NC USA
[6] Columbia Univ, Med Ctr, Crit Care Anesthesiol, Irving, NY USA
关键词
glucagon-like peptide-1 agonists; total hip and knee; perioperative management; diabetes; obesity; MORBIDLY OBESE;
D O I
10.1016/j.arth.2023.12.002
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Glucagon-Like Peptide agonists have traditionally been used for glycemic control in diabetic patients. However, there has been a dramatic rise in their utilization for weight loss management. As such, arthroplasty surgeons will encounter an increasing number of patients on these medications, and therefore it is important to understand the implications of their use in the perioperative period. This review will describe the pharmacological actions of these medications as well as the impact on hip and knee arthroplasty patients, and considerations for perioperative management. Because of the rapid adaption and utilization of these drugs, the science is evolving at a fast pace. More and longer-term studies are needed to truly understand the impact of these medications on total joint arthroplasty utilization and in management of these patients in the perioperative period. (c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:1455 / 1458
页数:4
相关论文
共 50 条
  • [41] Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation
    Hviid, Aleksander Vauvert R.
    Sorensen, Charlotte M.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2020, 318 (02) : F443 - F454
  • [42] Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus A Role in Cardiovascular Disease
    Smilowitz, Nathaniel R.
    Donnino, Robert
    Schwartzbard, Arthur
    CIRCULATION, 2014, 129 (22) : 2305 - 2312
  • [43] The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
    Tsiampali, Chara
    Papaioannidou, Paraskevi
    Goulas, Antonis
    Polyzos, Stergios A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (11) : 1063 - 1072
  • [44] Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?
    Lau, Darren
    Gamble, John-Michael
    DIABETES OBESITY & METABOLISM, 2024, 26 (04) : 1150 - 1156
  • [45] Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL
    Torekov, Signe Sorensen
    CARDIOVASCULAR RESEARCH, 2018, 114 (10) : E70 - E71
  • [46] Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity
    Burcelin, R.
    Gourdy, P.
    OBESITY REVIEWS, 2017, 18 (01) : 86 - 98
  • [48] The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review
    Kaye, Alan D.
    Sala, Kelly R.
    Abbott, Brennan M.
    Dicke, Alexandra N.
    Johnson, Landyn D.
    Wilson, Parker A.
    Amarasinghe, Sam N.
    Singh, Naina
    Ahmadzadeh, Shahab
    Kaye, Adam M.
    Shekoohi, Sahar
    Varrassi, Giustino
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [49] Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes
    Aschen, Seth Z.
    Zhang, Ashley
    O'Connell, Gillian M.
    Salingaros, Sophia
    Andy, Caroline
    Rohde, Christine H.
    Spector, Jason A.
    ANNALS OF SURGERY, 2025, 281 (04) : 600 - 607
  • [50] DIABETES AND OBESITY. THE ROLE OF AGONISTS GLUCAGON-LIKE PEPTIDE-1 OF IN THE TREATMENT OF TYPE 2 DIABETES
    Petunina, Nina A.
    Telnova, Milena E.
    DIABETES MELLITUS, 2018, 21 (04): : 293 - 300